| Company Name: |
Biolab Reagents Gold
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Zolbetuximab (DHF19801)
CAS:1496553-00-4
Purity:PAGE:>95% Package:100ug;1mg
|
| Company Name: |
Hangzhou Jiabiqi Biotechnology Co., Ltd. Gold
|
| Tel: |
18143428389 18143428389 |
| Email: |
443228489@qq.com |
| Products Intro: |
Product Name:Zolbetuximab
CAS:1496553-00-4
Purity:>95% Package:1mg;5mg;10mg;25mg;50mg;100mg
|
| Company Name: |
Wuhan Maixi Biotechnology Co., Ltd Gold
|
| Tel: |
18007167883 18007167883 |
| Email: |
Service@mabnus.com |
| Products Intro: |
Product Name:Zolbetuximab
CAS:1496553-00-4
Purity:>98% by SDS-PAGE Package:100μg/RMB 300
|
| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
13636370518 |
| Email: |
shyysw007@163.com |
| Products Intro: |
Product Name:Zolbetuximab (anti-CLDN18.2)
CAS:1496553-00-4
Purity:Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human I Package:100μg Remarks:K13590
|
Zolbetuximab manufacturers
- Zolbetuximab
-
- $263.00
-
2026-07-10
- CAS:1496553-00-4
- Purity: 97%+
- Supply Ability: 10g
|
| | Zolbetuximab Basic information |
| Product Name: | Zolbetuximab | | Synonyms: | Zolbetuximab;Research Grade Zolbetuximab (DHF19801);Zolbetuximab (IMAB362);Research Grade Zolbetuximab;Zolbetuximab (anti-CLDN18.2);IMAB362 | | CAS: | 1496553-00-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Zolbetuximab Structure]() |
| | Zolbetuximab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Zolbetuximab Usage And Synthesis |
| Uses | Zolbetuximab (development code IMAB362) is an experimental monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. | | Mechanism of action | Zolbetuximab is the first drug developed against the target of Claudin18.2. It is a chimeric IgG1 monoclonal antibody that specifically binds to Claudin18.2 on the surface of tumor cells, thereby triggering antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), apoptosis and inhibition of cell proliferation. | | in vivo | Zolbetuximab (200 μg, i.v.) alone and in combination with Gemcitabine (HY-17026) (50 mg/kg, i.p.) exhibits antitumor activity in mouse BxPC-3-CLDN18.2 xenograft models[2].
Zolbetuximab (5.7 mg/kg, i.p., three times per week for five weeks) inhibits tumor growth in SNU-620 cells xenograft model[3].
| Animal Model: | mouse BxPC-3-CLDN18.2, MIA PaCa-2-CLDN18.2 xenograft model[2] | | Dosage: | 200 μg alone or with 50 mg/kg Gemcitabine | | Administration: | i.v.; i.p. (Gemcitabine) | | Result: | Inhibited tumor growth in two models, and prevented lung metastasis formation.
Prolonged survival time, and lowered fractions of CLDN18.2+ cells in MIA PaCa-2-CLDN18.2 xenograft. |
|
| | Zolbetuximab Preparation Products And Raw materials |
|